COVID-19与慢性阻塞性肺疾病（COPD）的“基础”加重频率 - Suppr

Suppr

超能文献

COVID-19 and 'basal' exacerbation frequency in COPD.

作者信息

Cheng Daryl O, Hurst John R

机构信息

UCL Respiratory, University College London, London, UK.

UCL Respiratory, University College London, London, UK

出版信息

Thorax. 2021 May;76(5):432-433. doi: 10.1136/thoraxjnl-2020-216637. Epub 2020 Dec 22.

DOI:10.1136/thoraxjnl-2020-216637

PMID:33443208

Abstract

摘要

相似文献

COVID-19 and 'basal' exacerbation frequency in COPD.COVID-19与慢性阻塞性肺疾病（COPD）的“基础”加重频率

Thorax. 2021 May;76(5):432-433. doi: 10.1136/thoraxjnl-2020-216637. Epub 2020 Dec 22.

Hospital treatment of severe acute exacerbation of chronic obstructive pulmonary disease in COVID-19 situation: back to basics.2019冠状病毒病疫情下慢性阻塞性肺疾病严重急性加重的医院治疗：回归基础

Monaldi Arch Chest Dis. 2020 Sep 22;90(4). doi: 10.4081/monaldi.2020.1424.

Caring for patients with COPD and COVID-19: a viewpoint to spark discussion.关爱慢性阻塞性肺疾病（COPD）合并新型冠状病毒肺炎（COVID-19）患者：引发讨论的观点

Thorax. 2020 Dec;75(12):1035-1039. doi: 10.1136/thoraxjnl-2020-215095. Epub 2020 Sep 2.

Hospitalizations for Chronic Obstructive Pulmonary Disease Exacerbation During COVID-19.新冠疫情期间慢性阻塞性肺疾病急性加重的住院情况

JAMA Netw Open. 2024 May 1;7(5):e2412383. doi: 10.1001/jamanetworkopen.2024.12383.

Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections.吸烟人群和 COPD 患者小气道中内吞作用机制和 ACE2 的失调会增加其对 SARS-CoV-2（COVID-19）感染的易感性。

Am J Physiol Lung Cell Mol Physiol. 2021 Jan 1;320(1):L158-L163. doi: 10.1152/ajplung.00437.2020. Epub 2020 Nov 11.

Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.自噬增强以减轻免疫反应功能障碍，并解决呼吸和 COVID-19 恶化问题。

Cells. 2020 Aug 24;9(9):1952. doi: 10.3390/cells9091952.

Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights.哮喘、COPD 和 SARS-CoV-2 感染（COVID-19）：潜在的机制见解。

Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.00920-2021. Print 2021 Aug.

Characterization of COPD Admissions During the First COVID-19 Outbreak.首次新冠疫情期间 COPD 患者入院特征分析。

Int J Chron Obstruct Pulmon Dis. 2021 Jun 3;16:1549-1554. doi: 10.2147/COPD.S312493. eCollection 2021.

Clinical Courses and Outcomes of Patients with Chronic Obstructive Pulmonary Disease During the COVID-19 Epidemic in Hubei, China.中国湖北省 COVID-19 流行期间慢性阻塞性肺疾病患者的临床病程和结局。

Int J Chron Obstruct Pulmon Dis. 2020 Sep 23;15:2237-2248. doi: 10.2147/COPD.S265004. eCollection 2020.

Is a COPD patient protected against SARS-CoV-2 virus?慢性阻塞性肺疾病（COPD）患者对新型冠状病毒（SARS-CoV-2）有免疫力吗？

Infect Dis Now. 2021 Feb;51(1):98-99. doi: 10.1016/j.medmal.2020.09.015. Epub 2020 Oct 3.

引用本文的文献

Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study.日本慢性阻塞性肺疾病（COPD）合并中度气流受限患者的痰液微生物组、潜在致病生物与临床结局：前瞻性AERIS-J研究

Int J Chron Obstruct Pulmon Dis. 2025 May 14;20:1477-1492. doi: 10.2147/COPD.S481406. eCollection 2025.

Host Serine Proteases and Antiviral Innate Immunity as Potential Therapeutic Targets in Influenza A Virus Infection-Induced COPD Exacerbations.宿主丝氨酸蛋白酶与抗病毒天然免疫作为甲型流感病毒感染诱发慢性阻塞性肺疾病急性加重潜在治疗靶点

Int J Mol Sci. 2025 Mar 12;26(6):2549. doi: 10.3390/ijms26062549.

Non-pharmacologic Prevention of Acute Exacerbation Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病急性加重的非药物预防

Tuberc Respir Dis (Seoul). 2025 Jul;88(3):419-430. doi: 10.4046/trd.2024.0155. Epub 2025 Mar 7.

Predictive value of hematocrit, serum albumin level difference, and fibrinogen-to-albumin ratio for COVID-19-associated acute respiratory failure.血细胞比容、血清白蛋白水平差异及纤维蛋白原与白蛋白比值对新型冠状病毒肺炎相关急性呼吸衰竭的预测价值

Heliyon. 2024 Jun 20;10(12):e33326. doi: 10.1016/j.heliyon.2024.e33326. eCollection 2024 Jun 30.

Differences in hospital admissions for acute exacerbations of COPD during the COVID-19 pandemic stratified by stable-state blood eosinophil count.在新冠疫情期间，根据稳定状态下的血液嗜酸性粒细胞计数分层的慢性阻塞性肺疾病急性加重期住院情况差异。

Eur Respir J. 2023 Oct 12;62(4). doi: 10.1183/13993003.01125-2023. Print 2023 Oct.

Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control Study.抗SARS-CoV-2单克隆抗体和抗病毒药物可降低长期新冠风险：一项回顾性倾向评分匹配病例对照研究

Biomedicines. 2022 Dec 5;10(12):3135. doi: 10.3390/biomedicines10123135.

Air quality in Mexico City during the COVID-19 lockdown possibly decreased COPD exacerbations.在新冠疫情封锁期间，墨西哥城的空气质量可能降低了慢性阻塞性肺疾病（COPD）的急性加重发生率。

ERJ Open Res. 2022 Oct 10;8(4). doi: 10.1183/23120541.00183-2022. eCollection 2022 Oct.

Future Acceptability of Respiratory Virus Infection Control Interventions in General Population to Prevent Respiratory Infections.普通人群中预防呼吸道感染的呼吸道病毒感染控制干预措施的未来可接受性。

Medicina (Kaunas). 2022 Jun 22;58(7):838. doi: 10.3390/medicina58070838.

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality.新冠病毒感染发病率、严重程度和死亡率的风险和保护因素。

Clin Rev Allergy Immunol. 2023 Feb;64(1):90-107. doi: 10.1007/s12016-022-08921-5. Epub 2022 Jan 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验